All In Biotech

Drug Trial Radar · NCT01952223

A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse

A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 761 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

761

Actual

Start

Dec 2013

Primary completion

Dec 2025

Study completion Jul 2041

Sponsor

Lead sponsor
UNICANCERAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sanofi
First posted
Sep 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the effect of neoadjuvant cabazitaxel and pelvic radiotherapy in combination with androgen deprivation therapy (ADT)-radiotherapy on clinical progression-free survival in patients with high-risk localized prostate cancer (with a stringent selection of patients with at least 2 high-risk features), in a 2 by 2 factorial trial.

Conditions

  • Adenocarcinoma of Prostate
  • Progression of Prostate Cancer

Interventions

  • CabazitaxelDrug

    Cabazitaxel administered at 25 mg/m² as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles

  • Pelvic radiotherapyRadiation

    Prostate+pelvic RT (2 Gy fractions, 5 times per week): * Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center) * Phase 2: prostate-only boost (EBRT) up to 74-78 Gy

  • prostate radiotherapyRadiation

    Prostate-only RT (2 Gy fractions, 5 times per week): * Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center) * Phase 2: prostate-only boost (EBRT) up to 74-78 Gy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression free survivalTime frame: 10 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institut Gustave Roussy

    Villejuif, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.